- Home
- CMC vs GH Comparison
CMC vs GH Comparison
Compare CMC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMC
- GH
- Stock Information
- Founded
- CMC 1915
- GH 2011
- Country
- CMC United States
- GH United States
- Employees
- CMC N/A
- GH N/A
- Industry
- CMC Steel/Iron Ore
- GH Medical Specialities
- Sector
- CMC Industrials
- GH Health Care
- Exchange
- CMC Nasdaq
- GH Nasdaq
- Market Cap
- CMC 4.9B
- GH 5.5B
- IPO Year
- CMC 1987
- GH 2018
- Fundamental
- Price
- CMC $46.11
- GH $41.72
- Analyst Decision
- CMC Buy
- GH Strong Buy
- Analyst Count
- CMC 7
- GH 21
- Target Price
- CMC $60.33
- GH $52.81
- AVG Volume (30 Days)
- CMC 805.3K
- GH 2.7M
- Earning Date
- CMC 06-20-2025
- GH 04-30-2025
- Dividend Yield
- CMC 1.56%
- GH N/A
- EPS Growth
- CMC N/A
- GH N/A
- EPS
- CMC 0.63
- GH N/A
- Revenue
- CMC $7,738,612,000.00
- GH $773,996,000.00
- Revenue This Year
- CMC N/A
- GH $19.53
- Revenue Next Year
- CMC $8.41
- GH $21.92
- P/E Ratio
- CMC $73.02
- GH N/A
- Revenue Growth
- CMC N/A
- GH 28.20
- 52 Week Low
- CMC $37.92
- GH $18.01
- 52 Week High
- CMC $64.53
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- CMC 57.28
- GH 43.79
- Support Level
- CMC $44.67
- GH $38.86
- Resistance Level
- CMC $46.61
- GH $52.92
- Average True Range (ATR)
- CMC 1.23
- GH 2.91
- MACD
- CMC 0.38
- GH -0.74
- Stochastic Oscillator
- CMC 83.84
- GH 20.34
About CMC Commercial Metals Company
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.